Efficacy and safety of anlotinib for triple-negative breast cancer with brain metastases

被引：0

作者：

Liu, Zeyu ^{[1
]}

Li, Ming ^{[1
]}

Zhao, Ziyi ^{[2
]}

Liu, Aina ^{[1
]}

Sun, Ping ^{[1
]}

机构：

[1] Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Oncol, Yantai, Peoples R China

[2] Qingdao Univ, Dept Hand & Foot Microsurg, Affiliated Hosp, Qingdao, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

brain metastases; triple-negative breast cancer; anlotinib; tyrosine kinase inhibitor; antiangiogenesis; side effect; CELL LUNG-CANCER; RADIOTHERAPY; ANGIOGENESIS; BEVACIZUMAB; RECURRENT; RECEPTOR; THERAPY;

D O I：

10.3389/fonc.2024.1439984

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background The anti-angiogenic agent anlotinib offers a new treatment option for triple-negative breast cancer (TNBC) patients with brain metastases. This study aimed to evaluate the efficacy and safety of anlotinib in the treatment of TNBC patients with brain metastases.Methods Between October 2019 and April 2024, 29 TNBC patients with brain metastases who had failed prior therapy and were treated with anlotinib were retrospectively analyzed. The primary endpoint was central nervous system (CNS) progression-free survival (PFS), and secondary endpoints included overall survival (OS), intracranial disease control rate (iDCR), intracranial objective response rate (iORR), and safety.Results The median CNS PFS of 29 patients was 7.2 months (95% confidence interval [CI], 3.5-10.9 months), and the median OS was 10.2 months (95% CI, 5.6-14.8 months). The iORR and iDCR were 31.0% and 86.2%, respectively. Five patients (17.2%) experienced grade 3-4 adverse events (AEs), with bone marrow suppression (2/29, 6.9%) being the most common. Most AEs were clinically manageable, and no treatment-related death was observed.Conclusion Anlotinib demonstrated encouraging efficacy and manageable toxicity in the treatment of TNBC patients with brain metastases who had failed standard treatment.

引用

页数：9

共 37 条

[1] Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system [J].

Barnholtz-Sloan, JS ;

Sloan, AE ;

Davis, FG ;

Vigneau, FD ;

Lai, P ;

Sawaya, RE .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2865-2872

[2] Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort [J].

Darlix, Amelie ;

Louvel, Guillaume ;

Fraisse, Julien ;

Jacot, William ;

Brain, Etienne ;

Debled, Marc ;

Mouret-Reynier, Marie Ange ;

Goncalves, Anthony ;

Dalenc, Florence ;

Delaloge, Suzette ;

Campone, Mario ;

Augereau, Paule ;

Ferrero, Jean Marc ;

Levy, Christelle ;

Fumet, Jean-David ;

Lecouillard, Isabelle ;

Cottu, Paul ;

Petit, Thierry ;

Uwer, Lionel ;

Jouannaud, Christelle ;

Leheurteur, Marianne ;

Dieras, Veronique ;

Robain, Mathieu ;

Chevrot, Michael ;

Pasquier, David ;

Bachelot, Thomas .

BRITISH JOURNAL OF CANCER, 2019, 121 (12) :991-1000

[3] Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) [J].

Dickler, Maura N. ;

Barry, William T. ;

Cirrincione, Constance T. ;

Ellis, Matthew J. ;

Moynahan, Mary Ellen ;

Innocenti, Federico ;

Hurria, Arti ;

Rugo, Hope S. ;

Lake, Diana E. ;

Hahn, Olwen ;

Schneider, Bryan P. ;

Tripathy, Debasish ;

Carey, Lisa A. ;

Winer, Eric P. ;

Hudis, Clifford A. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (22) :2602-U86

[4]

FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182

[5] Mechanisms and Therapy for Cancer Metastasis to the Brain [J].

Franchino, Federica ;

Ruda, Roberta ;

Soffietti, Riccardo .

FRONTIERS IN ONCOLOGY, 2018, 8

[6] Anlotinib Combined with Cranial Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Retrospectively, Control Study [J].

He, Zelai ;

Liu, Jia ;

Ma, Yuwei ;

Jiang, Hao ;

Cui, Zhen ;

Wang, Guowen ;

Wu, Yufeng ;

Liu, Jiuzhou ;

Cai, Xixi ;

Qian, Jing ;

Huang, Jingwen ;

Zhang, Huijun ;

Li, Hongwei .

CANCER MANAGEMENT AND RESEARCH, 2021, 13 :6101-6111

[7] Brain volume reduction after whole-brain radiotherapy: quantification and prognostic relevance [J].

Hoffmann, Christian ;

Distel, Luitpold ;

Knippen, Stefan ;

Gryc, Thomas ;

Schmidt, Manuel Alexander ;

Fietkau, Rainer ;

Putz, Florian .

NEURO-ONCOLOGY, 2018, 20 (02) :268-278

[8] Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation [J].

Hou, Zhiwei ;

Wu, Huaguo ;

Luo, Ningning ;

Li, Shuo ;

Zhang, Xiang ;

Dong, Shuai ;

Zhu, Dongyuan ;

Zhang, Hui ;

Tao, Rongjie .

ONCOLOGIST, 2023, 28 (05) :449-452

[9] Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer [J].

Hu, Nanlin ;

Si, Yiran ;

Yue, Jian ;

Sun, Tingting ;

Wang, Xue ;

Jia, Zhuqing ;

Gao, Songlin ;

Li, Qiao ;

Shao, Yang ;

Wang, Jiayu ;

Luo, Yang ;

Ma, Fei ;

Xu, Binghe ;

Yuan, Peng .

CANCER BIOLOGY & MEDICINE, 2021, 18 (03) :849-+

[10] Intracranial complete response to toripalimab and anlotinib in a patient with recurrent brain metastases of small cell lung cancer after failure of second-line maintenance therapy: a case report [J].

Huang, Fengxiang ;

Tang, Jiaqi ;

Lou, Jiaojiao ;

Wang, Qilong ;

Ma, Kai ;

Qiao, Ruiping ;

Si, Jiming ;

Kang, Yan ;

Chen, Hongjie ;

Mei, Jingjing ;

Wang, Huanqin ;

Liu, Yuanhua ;

Miao, Lijun .

TRANSLATIONAL CANCER RESEARCH, 2022, 11 (09) :3337-3342

← 1 2 3 4 →